Ventyx Biosciences, Inc. Stock

Equities

VTYX

US92332V1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
4.35 USD -0.68% Intraday chart for Ventyx Biosciences, Inc. -5.43% +76.11%
Sales 2024 * - Sales 2025 * - Capitalization 307M
Net income 2024 * -168M Net income 2025 * -193M EV / Sales 2024 * -
Net cash position 2024 * 208M Net cash position 2025 * 339M EV / Sales 2025 * -
P/E ratio 2024 *
-1.56 x
P/E ratio 2025 *
-1.56 x
Employees 80
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.79%
More Fundamentals * Assessed data
Dynamic Chart
Ventyx Biosciences, Inc. Announces Resignation of Christopher Krueger as Chief Business Officer, Effective on April 15, 2024 CI
Transcript : Ventyx Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM
Canaccord Genuity Trims Price Target on Ventyx Biosciences to $15 From $16, Maintains Buy Rating MT
North American Morning Briefing : Stock Futures -2- DJ
Ventyx Biosciences Shares Rise After Oppenheimer, Wells Fargo Upgrades MT
Oppenheimer Upgrades Ventyx Biosciences to Outperform From Perform, $12 Price Target MT
Wells Fargo Upgrades Ventyx Biosciences to Overweight From Equal Weight, Raises Price Target to $16 From $7 MT
Canaccord Genuity Adjusts Ventyx Biosciences' Price Target to $16 From $20, Maintains Buy Rating MT
Transcript : Ventyx Biosciences, Inc. - Special Call
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event CI
Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in funding CI
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target MT
Ventyx Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ventyx Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Wells Fargo Cuts Ventyx Biosciences Price Target to $3 From $8, Maintains Equal Weight Rating MT
More news
1 day-0.68%
1 week-5.43%
Current month-20.91%
1 month-45.49%
3 months+128.95%
6 months-75.14%
Current year+76.11%
More quotes
1 week
4.24
Extreme 4.235
4.83
1 month
4.24
Extreme 4.235
7.95
Current year
1.87
Extreme 1.865
11.48
1 year
1.87
Extreme 1.865
40.58
3 years
1.87
Extreme 1.865
47.25
5 years
1.87
Extreme 1.865
47.25
10 years
1.87
Extreme 1.865
47.25
More quotes
Managers TitleAgeSince
Founder 68 18-10-31
Director of Finance/CFO 49 21-04-30
Chief Tech/Sci/R&D Officer 65 18-12-31
Members of the board TitleAgeSince
Director/Board Member 69 18-10-31
Director/Board Member 61 23-01-10
Chairman 53 21-04-30
More insiders
Date Price Change Volume
24-04-18 4.35 -0.68% 849,825
24-04-17 4.38 -7.98% 780,158
24-04-16 4.76 +1.93% 661,262
24-04-15 4.67 +1.52% 628,944
24-04-12 4.6 0.00% 674,166

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
4.38 USD
Average target price
10.8 USD
Spread / Average Target
+146.58%
Consensus